Pacific Edge Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
100
- Stock Symbol
-
PEB
- Share Price
-
$0.15
- (As of Friday Closing)
Pacific Edge General Information
Description
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
Contact Information
Website
www.pacificedgedx.comCorporate Office
- 87 Street David Street
- PO Box 56
- Dunedin, 9016
- New Zealand
Corporate Office
- 87 Street David Street
- PO Box 56
- Dunedin, 9016
- New Zealand
Pacific Edge Timeline
Pacific Edge Stock Performance
As of 13-Nov-2026, Pacific Edge’s stock price is $0.15. Its current market cap is $189M with 1.24B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.15 | $0.16 | $0.08 - $0.20 | $189M | 1.24B | 741K | -$0.02 |
Pacific Edge Financials Summary
As of 31-Mar-2026, Pacific Edge has a trailing 12-month revenue of $6.75M.
|
In Thousands, USD |
TTM 31-Mar-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 90,392 | 90,392 | 42,082 | 4,909 |
| Revenue | 6,747 | 6,747 | 12,926 | 14,561 |
| EBITDA | (20,569) | (20,569) | (17,983) | (18,900) |
| Net Income | (20,994) | (20,994) | (17,712) | (17,989) |
| Total Assets | 10,061 | 10,061 | 21,128 | 39,033 |
| Total Debt | 735 | 735 | 1,655 | 2,429 |
Pacific Edge Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pacific Edge Comparisons
Industry
Financing
Details
Pacific Edge Competitors (4)
One of Pacific Edge’s 4 competitors is Qiagen, a Formerly VC-backed company based in Hilden, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Qiagen | Formerly VC-backed | Hilden, Germany | ||||
| Abbott | Corporation | Abbot Park, IL | ||||
| KDx Diagnostics | Venture Capital-Backed | Los Gatos, CA | ||||
| Nucleix | Venture Capital-Backed | Rehovot, Israel |
Pacific Edge Patents
Pacific Edge Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026190756-A1 | Methods and systems for patient stratification | Pending | 14-Mar-2025 | ||
| US-10131955-B2 | Methods for detecting genetic and phenotypic biomarkers of urothelial carcinoma and treatment thereof | Active | 21-Nov-2013 | ||
| US-20190203300-A1 | Methods for treating urothelial carcinoma using genotypic and phenotypic biomarkers | Inactive | 21-Nov-2013 | ||
| ES-2844202-T3 | Triage of patients who have asymptomatic hematuria using genotypic and phenotypic biomarkers | Active | 21-Nov-2013 | ||
| AU-2014352956-A1 | Triaging of patients having asymptomatic hematuria using genotypic and phenotypic biomarkers | Active | 21-Nov-2013 | C12Q1/6886 |
Pacific Edge Signals
Pacific Edge Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Pacific Edge ESG
Risk Overview
Risk Rating
Updated February, 28, 2025
37.56 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Biotechnology
Subindustry
of 434
Rank
Percentile
Pacific Edge FAQs
-
When was Pacific Edge founded?
Pacific Edge was founded in 2001.
-
Where is Pacific Edge headquartered?
Pacific Edge is headquartered in Dunedin, New Zealand.
-
What is the size of Pacific Edge?
Pacific Edge has 100 total employees.
-
What industry is Pacific Edge in?
Pacific Edge’s primary industry is Discovery Tools (Healthcare).
-
Is Pacific Edge a private or public company?
Pacific Edge is a Public company.
-
What is Pacific Edge’s stock symbol?
The ticker symbol for Pacific Edge is PEB.
-
What is the current stock price of Pacific Edge?
As of 13-Nov-2026 the stock price of Pacific Edge is $0.15.
-
What is the current market cap of Pacific Edge?
The current market capitalization of Pacific Edge is $189M.
-
What is Pacific Edge’s current revenue?
The trailing twelve month revenue for Pacific Edge is $6.75M.
-
Who are Pacific Edge’s competitors?
Qiagen, Abbott, KDx Diagnostics, and Nucleix are competitors of Pacific Edge.
-
What is Pacific Edge’s annual earnings per share (EPS)?
Pacific Edge’s EPS for 12 months was -$0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process